Johnson & Johnson antibody drug Imaavy expanded its label to include the treatment of warm autoimmune hemolytic anemia (wAIHA). Projected to become a blockbuster seller across multiple indications, Imaavy was first approved last year for treating generalized myasthenia gravis.
The post J&J’s Imaavy Becomes First FDA-Approved Therapy for Rare Form of Anemia appeared first on MedCity News.
